Targeted Therapies in Cancer

Marc Lacroix (Editor)
Université Libre de Bruxelles, Baelen, Belgium

Series: Cancer Etiology, Diagnosis and Treatments
BISAC: MED062000

Clear

$145.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

Since the year 2000, exciting developments in cancer therapy have occurred. For decades in the 20th century, the hallmark of medical treatment for cancer had been cytotoxic chemotherapy, with drugs targeting rapidly dividing cells, including cancer cells but also certain normal tissues. As a result, many patients experienced the “classic” toxicities of alopecia, gastrointestinal symptoms and/or myelosuppression. In the last years, however, clinical research has been strongly occupied with the identification of mutations and aberrations concerning molecular pathways in cancer and their alterations, which has enabled the emergence of a “targeted” (somewhat personalized) medicine approach to treatment.

Today, although traditional cytotoxic chemotherapy remains the treatment of choice for many malignancies, notably as first-line agents, targeted therapies are a possible choice for many types of cancer, including breast, prostate, CRC, lung, kidney cancers, as well as lymphoma, leukemia, and myeloma. More than 60 of these targeted therapies recently approved by the United States Food and Drug Administration (FDA) are detailed in the book, and their intended use in one or more cancer types are shown. (Imprint: Nova Biomedical )

Preface

Chapter 1 - Innovation in the Biopharmaceutical Pipeline (pp. 1-4)

Chapter 2 - The Diversity of Targeted Cancer Drugs Recently Approved by the FDA (pp. 5-14)

Chapter 3 - Chronological List of Targeted Cancer Drugs Approved by the FDA (pp. 15-22)

Chapter 4 - Targeted Therapies: Detailed Description (pp. 23-68)

Chapter 5 - Targeted Therapy for Chronic Lymphocytic Leukemia (CLL) (pp. 69-80)

Chapter 6 - Targeted Therapy for HER-2-Positive Breast Cancer (pp. 81-90)

Chapter 7 - Targeted Therapy for Metastatic Breast Cancer: Varia (pp. 91-96)

Chapter 8 - Targeted Therapy for Chronic Myelogenous Leukemia (CML) (pp. 97-108)

Chapter 9 - Targeted Therapy for Gastrointestinal Stromal Tumors (GIST) (pp. 109-116)

Chapter 10 - Targeted Therapy for Metastatic Colorectal Cancer (mCRC) (pp. 117-132)

Chapter 11 - Targeted Therapy for Metastatic Melanoma (McM) (pp. 133-146)

Chapter 12 - Targeted Therapy for Multiple Myeloma (MM) (pp. 147-156)

Chapter 13 - Targeted Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC) (pp. 157-168)

Chapter 14 - Targeted Therapy for Metastatic Renal Cell Carcinoma (mRCC) (pp. 169-180)

Chapter 15 - Targeted Therapy for Gastric Cancer (pp. 181-186)

Chapter 16 - Targeted Therapy for Non-Small Cell Lung Cancer (NSCLC) (pp. 187-202)

Chapter 17 - Targeted Therapy for Myelodysplastic Syndromes (MDS) (pp. 203-208)

Chapter 18 - Targeted Therapy for Mantle Cell Lymphoma (MCL) (pp. 209-214)

Chapter 19 - Abbreviations (pp. 215-218)

Chapter 20 - Generic Names – Trade Names: Equivalences (pp. 219-222)

Index

You have not viewed any product yet.